Vagus Nerve Stimulators Market to Reach Significant Growth at 8.9% CAGR through 2031, Driven by Rising Prevalence of Epilepsy and Depression | DataM Intelligence

According to DataM Intelligence, the global Vagus Nerve Stimulators market is expected to grow at a CAGR of 8.9% during the forecast period 2024-2031, driven by increasing incidence of treatment-resistant epilepsy and depression, strong adoption of implantable VNS devices, expanding applications in migraine management, growing demand for non-invasive external stimulators, and rapid market penetration in Asia-Pacific with rising neurological disorder awareness.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/vagus-nerve-stimulators-market?jd

United States Key Industry Developments

☑️ January 2026: Medtronic PLC expanded U.S. availability of its latest implantable VNS systems with enhanced programming features, securing additional reimbursement approvals for epilepsy and depression indications.
☑️ January 2026: LivaNova PLC reported strong adoption of its VNS therapy devices in major epilepsy centers, launching patient support programs to improve long-term outcomes.
☑️ December 2025: Electrocore LLC advanced its non-invasive gammaCore external VNS device with new clinical data for migraine prevention, gaining wider insurance coverage across U.S. healthcare networks.

Japan Key Industry Developments

☑️ January 2026: Japanese medical device firms accelerated regulatory approvals for implantable and external VNS devices, supported by updated guidelines for refractory epilepsy and depression treatment.
☑️ January 2026: Local and global players showcased advanced VNS technologies at major Tokyo neurology expos, emphasizing applications in chronic migraine and treatment-resistant depression.
☑️ December 2025: Growing integration of VNS devices in Japanese hospitals and specialty clinics, driven by rising awareness of neuromodulation benefits for neurological disorders.

Key Mergers and Acquisitions

✦ January 2026: Medtronic PLC acquired a neuromodulation tech startup to enhance its implantable VNS device capabilities for epilepsy and depression indications.
✦ December 2025: LivaNova PLC completed a bolt-on acquisition of a neurostimulation IP portfolio to strengthen its VNS therapy pipeline for migraine and other applications.
✦ November 2025: Electrocore LLC secured a licensing agreement with an external stimulation innovator to integrate advanced non-invasive features into its gammaCore platform.

Purchase the report to unlock market insights:
https://www.datamintelligence.com/buy-now-page?report=vagus-nerve-stimulators-market

Market Segmentation Analysis

By Type: Implantable VNS Devices hold the largest share due to established efficacy in refractory epilepsy and depression, with long-term stimulation benefits; External VNS Devices grow fastest for non-invasive migraine treatment and patient convenience.

By Application: Epilepsy dominates with the highest share driven by FDA-approved VNS as adjunct therapy for drug-resistant cases; Depression follows closely for treatment-resistant major depressive disorder; Migraine expands rapidly with non-invasive external VNS approvals and clinical evidence.

By End-User: Hospitals lead with major share for surgical implantation and initial programming of VNS devices; Ambulatory Surgical Centers (ASCs) grow steadily for minimally invasive procedures; Others include specialty neurology clinics and outpatient settings.

By Biomaterial: Polymeric materials dominate for flexible leads and biocompatibility; Metallic components remain essential for electrodes and pulse generators; Ceramics grow in niche high-reliability applications.

Regional Insights

North America commands the largest market share in the global Vagus Nerve Stimulators market, supported by high prevalence of treatment-resistant epilepsy and depression, rapid FDA approvals for implantable and external VNS devices, advanced neuromodulation infrastructure, strong reimbursement for approved indications, and presence of leading manufacturers driving clinical adoption.

Asia-Pacific remains the fastest-growing region, fueled by increasing neurological disorder burden, rising awareness of VNS therapy, expanding specialty clinics and hospitals, government initiatives for advanced medical devices, growing clinical trial participation, and aggressive market entry by global players targeting epilepsy, depression, and migraine applications.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/vagus-nerve-stimulators-market?jd

Growth Drivers

-Increasing prevalence of drug-resistant epilepsy and depression requiring neuromodulation
-Growing approvals and clinical evidence supporting VNS efficacy in multiple indications
-Rising demand for non-invasive external VNS devices for migraine management
-Expanding healthcare infrastructure and specialty neurology centers in emerging markets
-Advancements in implantable device technology improving patient outcomes and comfort

Key Players

The market includes leading companies such as Medtronic PLC, Electrocore LLC, Livanova PLC, Boston Scientific Corporation, Aleva Neurotherapeutics SA, Biocontrol Medical, Bioness Inc., Enteromedics Inc., Nevro Corporation, Neuropace Inc., and others.

Key Highlights (Top 5 Key Players)

✦ Medtronic PLC - Leading global provider of implantable VNS devices with established therapies for epilepsy and depression, strong focus on long-term efficacy and patient support programs.
✦ LivaNova PLC - Renowned for VNS therapy systems targeting epilepsy and treatment-resistant depression, emphasizing clinical evidence and expanded indications.
✦ Electrocore LLC - Specialized in non-invasive gammaCore external VNS devices for migraine prevention, with rapid adoption in neurology clinics.
✦ Boston Scientific Corporation - Strong in neuromodulation technologies, advancing VNS solutions for chronic pain and neurological disorders.
✦ Nevro Corporation - Innovating in neurostimulation with potential crossover applications to VNS for pain and related conditions.

Unlock 360° Market Intelligence with DataM Intelligence Subscription Services:
https://www.datamintelligence.com/reports-subscription?jd

Power your decisions with real time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape Analysis
✅ Company Profile Analysis
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updates
✅ Live Market & Pricing Trends
✅ Regulatory and Supply Chain Analysis
Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.